$ORGO
Organogenesis Holdings Inc.

2020 Q2 Form 10-Q Financial Statement

#000119312520214949 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $68.96M $64.95M $57.12M
YoY Change 6.18% 49.13% 60.78%
Cost Of Revenue $20.04M $19.45M $16.98M
YoY Change 3.06% 12.4% 16.93%
Gross Profit $48.92M $45.50M $40.14M
YoY Change 7.51% 73.33% 91.08%
Gross Profit Margin 70.94% 70.06% 70.27%
Selling, General & Admin $46.50M $48.96M $48.89M
YoY Change -5.01% 29.74% 28.11%
% of Gross Profit 95.06% 107.59% 121.8%
Research & Development $4.668M $3.864M $3.371M
YoY Change 20.81% 88.67% 19.37%
% of Gross Profit 9.54% 8.49% 8.4%
Depreciation & Amortization $891.0K $859.0K $902.0K
YoY Change 3.73% -1.83% 3.44%
% of Gross Profit 1.82% 1.89% 2.25%
Operating Expenses $51.17M $52.82M $52.26M
YoY Change -3.13% 22.05% 27.51%
Operating Profit -$2.252M -$7.319M -$12.12M
YoY Change -69.23% -57.01% -39.34%
Interest Expense $2.912M $2.187M $1.778M
YoY Change 33.15% -21.36% -26.8%
% of Operating Profit
Other Income/Expense, Net -$2.887M -$2.307M -$3.508M
YoY Change 25.14% -22.01% 41.51%
Pretax Income -$5.139M -$9.626M -$15.63M
YoY Change -46.61% -51.83% -30.41%
Income Tax $27.00K $23.00K $37.00K
% Of Pretax Income
Net Earnings -$5.166M -$9.649M -$15.67M
YoY Change -46.46% -51.78% -30.34%
Net Earnings / Revenue -7.49% -14.86% -27.43%
Basic Earnings Per Share
Diluted Earnings Per Share -$49.67K -$106.0K -$173.3K
COMMON SHARES
Basic Shares Outstanding 106.1M 91.32M 92.01M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.50M $20.00M $30.60M
YoY Change 102.5% 19900.0% 30500.0%
Cash & Equivalents $40.75M $20.16M $30.66M
Short-Term Investments
Other Short-Term Assets $4.700M $3.200M $4.000M
YoY Change 46.88% 3100.0% 1900.0%
Inventory $28.56M $18.72M $17.97M
Prepaid Expenses
Receivables $44.02M $34.16M $32.51M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $117.7M $76.15M $85.06M
YoY Change 54.58% 37973.0% 28254.0%
LONG-TERM ASSETS
Property, Plant & Equipment $53.03M $40.75M $39.45M
YoY Change 30.14%
Goodwill $25.54M $25.54M $25.54M
YoY Change 0.0%
Intangibles $19.16M $23.84M $24.59M
YoY Change -19.63%
Long-Term Investments
YoY Change
Other Assets $728.0K $1.040M $1.072M
YoY Change -30.0% -99.67% -99.66%
Total Long-Term Assets $98.78M $91.93M $91.39M
YoY Change 7.45% -70.8% -70.85%
TOTAL ASSETS
Total Short-Term Assets $117.7M $76.15M $85.06M
Total Long-Term Assets $98.78M $91.93M $91.39M
Total Assets $216.5M $168.1M $176.5M
YoY Change 28.8% -46.64% -43.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $29.94M $22.28M $24.58M
YoY Change 34.41%
Accrued Expenses $24.69M $20.68M $20.40M
YoY Change 19.39% 282.94% 324.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $10.00M $2.400M $2.300M
YoY Change 316.67%
Total Short-Term Liabilities $66.06M $50.40M $52.31M
YoY Change 31.07% 754.22% 925.63%
LONG-TERM LIABILITIES
Long-Term Debt $105.3M $39.66M $39.64M
YoY Change 165.49%
Other Long-Term Liabilities $8.264M $6.220M $5.680M
YoY Change 32.86% -42.94% -47.89%
Total Long-Term Liabilities $8.264M $45.88M $45.32M
YoY Change -81.99% 320.94% 315.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $66.06M $50.40M $52.31M
Total Long-Term Liabilities $8.264M $45.88M $45.32M
Total Liabilities $180.7M $144.9M $143.9M
YoY Change 24.75% 767.52% 804.99%
SHAREHOLDERS EQUITY
Retained Earnings -$192.5M -$155.2M -$145.6M
YoY Change 24.01%
Common Stock $228.2M $178.4M $178.1M
YoY Change 27.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $728.5K $728.5K $728.5K
Shareholders Equity $35.75M $23.20M $32.56M
YoY Change
Total Liabilities & Shareholders Equity $216.5M $168.1M $176.5M
YoY Change 28.8% -46.64% -43.77%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$5.166M -$9.649M -$15.67M
YoY Change -46.46% -51.78% -30.34%
Depreciation, Depletion And Amortization $891.0K $859.0K $902.0K
YoY Change 3.73% -1.83% 3.44%
Cash From Operating Activities -$9.340M -$12.11M -$9.558M
YoY Change -22.87% 5666.67% 114.45%
INVESTING ACTIVITIES
Capital Expenditures -$2.170M -$1.180M $317.0K
YoY Change 83.9% 387.69%
Acquisitions
YoY Change
Other Investing Activities $290.0K
YoY Change
Cash From Investing Activities -$1.880M -$1.180M -$317.0K
YoY Change 59.32% 387.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.890M 2.800M 19.13M
YoY Change 74.64% 1455.56% 520.8%
NET CHANGE
Cash From Operating Activities -9.340M -12.11M -9.558M
Cash From Investing Activities -1.880M -1.180M -317.0K
Cash From Financing Activities 4.890M 2.800M 19.13M
Net Change In Cash -6.330M -10.49M 9.258M
YoY Change -39.66% 34866.67% -742.92%
FREE CASH FLOW
Cash From Operating Activities -$9.340M -$12.11M -$9.558M
Capital Expenditures -$2.170M -$1.180M $317.0K
Free Cash Flow -$7.170M -$10.93M -$9.875M
YoY Change -34.4% 118.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Assets
Assets
220687000
CY2020Q2 orgo Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
24688000
CY2019Q4 orgo Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
23450000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
66058000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59894000
CY2020Q2 us-gaap Liabilities
Liabilities
180737000
CY2019Q4 us-gaap Liabilities
Liabilities
165104000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
228225000
CY2020Q2 us-gaap Cash
Cash
40455000
CY2019Q4 us-gaap Cash
Cash
60174000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
117706000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
125600000
CY2020Q2 us-gaap Assets
Assets
216487000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
226580000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192486000
CY2020Q2 us-gaap Revenues
Revenues
68960000
CY2019Q2 us-gaap Revenues
Revenues
64948000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
20042000
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
19446000
CY2020Q2 us-gaap Gross Profit
GrossProfit
48918000
CY2019Q2 us-gaap Gross Profit
GrossProfit
45502000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46502000
us-gaap Revenues
Revenues
130692000
us-gaap Revenues
Revenues
122071000
us-gaap Cost Of Revenue
CostOfRevenue
38835000
us-gaap Cost Of Revenue
CostOfRevenue
36426000
us-gaap Gross Profit
GrossProfit
91857000
us-gaap Gross Profit
GrossProfit
85645000
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48957000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4668000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3864000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
51170000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
52821000
CY2020Q2 us-gaap Interest Expense
InterestExpense
2912000
CY2019Q2 us-gaap Interest Expense
InterestExpense
2187000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-120000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
99115000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
97850000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10078000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7235000
us-gaap Operating Expenses
OperatingExpenses
109193000
us-gaap Operating Expenses
OperatingExpenses
105085000
us-gaap Interest Expense
InterestExpense
5422000
us-gaap Interest Expense
InterestExpense
3965000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
90625850
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
216487000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220687000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2252000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7319000
us-gaap Profit Loss
ProfitLoss
-21479000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
104714725
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
90647352
us-gaap Operating Income Loss
OperatingIncomeLoss
-17336000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19440000
us-gaap Profit Loss
ProfitLoss
-25315000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
104600825
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171007000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
35750000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
55583000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1862000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2887000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2307000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5139000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9626000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5166000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-9649000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
46000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4081000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5815000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21417000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25255000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
62000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
us-gaap Net Income Loss
NetIncomeLoss
-21479000
us-gaap Net Income Loss
NetIncomeLoss
-25315000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
32559000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
47041000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
40295000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-54000
orgo Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
-628000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-152000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-968000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-54000
CY2020Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
299000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
196000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
44024000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39359000
CY2020Q2 us-gaap Inventory Net
InventoryNet
28562000
CY2019Q4 us-gaap Inventory Net
InventoryNet
22918000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4366000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2953000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53033000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47184000
CY2020Q2 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
302000
CY2019Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
556000
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19164000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20797000
CY2020Q2 us-gaap Goodwill
Goodwill
25539000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-234000
CY2019Q2 us-gaap Profit Loss
ProfitLoss
-9649000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
23198000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-458000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-469000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-5166000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-678000
us-gaap Depreciation
Depreciation
1793000
us-gaap Depreciation
Depreciation
1761000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1633000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2997000
orgo Non Cash Interest Expense
NonCashInterestExpense
103000
orgo Non Cash Interest Expense
NonCashInterestExpense
154000
orgo Deferred Interest Expense
DeferredInterestExpense
1022000
orgo Deferred Interest Expense
DeferredInterestExpense
536000
orgo Non Cash Rent Expense Income
NonCashRentExpenseIncome
64000
orgo Non Cash Rent Expense Income
NonCashRentExpenseIncome
326000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
970000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
27000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-201000
us-gaap Share Based Compensation
ShareBasedCompensation
678000
us-gaap Share Based Compensation
ShareBasedCompensation
458000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1862000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5727000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-723000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7353000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6087000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1302000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
785000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
235000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1473000
orgo Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
1266000
orgo Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
122000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1501000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
7000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
17585000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
968000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
849000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13120000
CY2020Q2 orgo Deferred Acquisition Consideration Liability Current
DeferredAcquisitionConsiderationLiabilityCurrent
1432000
CY2019Q4 orgo Deferred Acquisition Consideration Liability Current
DeferredAcquisitionConsiderationLiabilityCurrent
5000000
CY2020Q2 us-gaap Secured Debt Current
SecuredDebtCurrent
6667000
CY2020Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3327000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
864000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-449000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26618000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21674000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6411000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1251000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6118000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21929000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19616000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1246000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60370000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21405000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40754000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20159000
us-gaap Interest Paid
InterestPaid
4626000
us-gaap Interest Paid
InterestPaid
3890000
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Income Taxes Paid
IncomeTaxesPaid
67000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
75000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192486000
CY2020Q2 orgo Working Capital
WorkingCapital
51648000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
5869000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
54000
CY2019Q4 us-gaap Goodwill
Goodwill
25539000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
728000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
884000
CY2019Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3057000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
29944000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
28387000
CY2020Q2 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
39353000
CY2019Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
33484000
CY2020Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1097000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1012000
CY2020Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
13011000
CY2019Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
14431000
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8264000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6649000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
11000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7179636
CY2020Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
47952000
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
42408000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3928000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3049000
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3204000
CY2019Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3292000
CY2020Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
753000
CY2019Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
103000
CY2020Q2 orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-29000
CY2019Q2 orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-374000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3928000
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3021000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9178000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
781000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12959000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
67604000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
65812000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
86159000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
82774000
CY2020Q2 us-gaap Depreciation
Depreciation
891000
CY2019Q2 us-gaap Depreciation
Depreciation
859000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
816000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1499000
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32830000
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13666000
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19164000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32830000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12033000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20797000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19062000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17640000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5626000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5810000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24688000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23450000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
469000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
234000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
678000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
458000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.98
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20799000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
546282
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
334771
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.48
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7837306
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.34
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5492502
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y5M8D
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12694000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7326832
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.21
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y7M24D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
12904000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
209000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
344000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25006426
CY2020Q2 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
2396000
CY2020Q2 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
4786000
CY2020Q2 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
4945000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8695401
CY2020Q2 us-gaap Capital Leases Future Minimum Payments Net Minimum Payments1
CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1
21966000
CY2020Q2 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
5628000
CY2020Q2 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
16338000
CY2020Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3327000
CY2020Q2 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
43850000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1837000
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1603000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3351000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2925000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
2884000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
5627000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3094000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2361000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1224000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6899000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
22089000
CY2020Q2 orgo Accrued Legal Expenses
AccruedLegalExpenses
1109000
CY2019Q4 orgo Accrued Legal Expenses
AccruedLegalExpenses
542000
CY2019Q4 orgo Business Combination Deferred Consideration
BusinessCombinationDeferredConsideration
5000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106145716
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105599434
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105417168
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104870886
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1538723
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.04
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
10000000
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
40000000
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
6762000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1149000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
557000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4692000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1638000
us-gaap Net Income Loss
NetIncomeLoss
-21479000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26618000
CY2020Q2 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
837000
CY2019Q2 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
731000
us-gaap Administrative Fees Expense
AdministrativeFeesExpense
1797000
us-gaap Administrative Fees Expense
AdministrativeFeesExpense
1111000
CY2019Q2 orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
265000
orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
523000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
16667000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
20000000
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
99353000
CY2020Q2 orgo Shares Reserved For Issuance For Outstanding Options
SharesReservedForIssuanceForOutstandingOptions
7161316
CY2019Q4 orgo Shares Reserved For Issuance For Outstanding Options
SharesReservedForIssuanceForOutstandingOptions
6503646
CY2020Q2 orgo Shares Reserved For Issuance For Future Grant
SharesReservedForIssuanceForFutureGrant
6612178
CY2019Q4 orgo Shares Reserved For Issuance For Future Grant
SharesReservedForIssuanceForFutureGrant
9008996
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14631589
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15512642
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1552000
CY2020Q2 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
9839000
CY2017 orgo Business Combinationdeferred Consideration Payment
BusinessCombinationdeferredConsiderationPayment
2500000
CY2020Q2 us-gaap Secured Long Term Debt
SecuredLongTermDebt
52954000
CY2019Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
49634000
orgo Gain Loss On Deferred Acquisition Consideration Settlement
GainLossOnDeferredAcquisitionConsiderationSettlement
1295000
orgo Gain Loss On Deferred Acquisition Consideration Settlement
GainLossOnDeferredAcquisitionConsiderationSettlement
1295000
orgo Adjustment For Excess And Obsolete Inventories
AdjustmentForExcessAndObsoleteInventories
-1709000
orgo Adjustment For Excess And Obsolete Inventories
AdjustmentForExcessAndObsoleteInventories
-523000
orgo Payments Of Deferred Acquisition Consideration
PaymentsOfDeferredAcquisitionConsideration
2568000
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Organogenesis Holdings Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001661181
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
42686000
CY2020Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
728548
CY2020Q2 orgo Shares Reserved For Issuance For Outstanding Restricted Stock Units
SharesReservedForIssuanceForOutstandingRestrictedStockUnits
858095
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
873595
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
15500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.04
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
858095
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.81
CY2019 orgo Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Options Outstanding Weighted Average Remaining Contractual Terms
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOptionsOutstandingWeightedAverageRemainingContractualTerms
P5Y21D
orgo Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Options Outstanding Weighted Average Remaining Contractual Terms
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOptionsOutstandingWeightedAverageRemainingContractualTerms
P5Y10M24D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12933000
us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
4000000
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
2000000
CY2020Q2 orgo Remaining Litigation Settlement Amount Payable
RemainingLitigationSettlementAmountPayable
2000000
CY2020Q2 orgo Remaining Litigation Settlement Amount Payable Per Quarter
RemainingLitigationSettlementAmountPayablePerQuarter
500000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
1295000
CY2020Q2 us-gaap Interest Income Related Party
InterestIncomeRelatedParty
20000
CY2019Q2 us-gaap Interest Income Related Party
InterestIncomeRelatedParty
20000
us-gaap Interest Income Related Party
InterestIncomeRelatedParty
40000
us-gaap Interest Income Related Party
InterestIncomeRelatedParty
39000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
250000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
628000
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
293000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
500000
CY2020Q2 orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
940000
orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
1709000
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Trading Symbol
TradingSymbol
ORGO
dei Security12b Title
Security12bTitle
Class A Common Stock, $0.0001 par value
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
105417168
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15000
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
127000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1559000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3049000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3420000
orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-91000
orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-426000
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9591000
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
17412000
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'times new roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure as of the date of the consolidated financial statements and the reported results of operations during the reporting period. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001193125-20-214949-index-headers.html Edgar Link pending
0001193125-20-214949-index.html Edgar Link pending
0001193125-20-214949.txt Edgar Link pending
0001193125-20-214949-xbrl.zip Edgar Link pending
d945496d10q.htm Edgar Link pending
d945496dex311.htm Edgar Link pending
d945496dex312.htm Edgar Link pending
d945496dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
orgo-20200630.xml Edgar Link completed
orgo-20200630.xsd Edgar Link pending
orgo-20200630_cal.xml Edgar Link unprocessable
orgo-20200630_def.xml Edgar Link unprocessable
orgo-20200630_lab.xml Edgar Link unprocessable
orgo-20200630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending